Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate aTyr Pharma, Inc. before investing.

In this article, we go over a few key elements for understanding aTyr Pharma, Inc.’s stock price such as:

• aTyr Pharma, Inc.’s current stock price and volume
• Why aTyr Pharma, Inc.’s stock price changed recently
• Upgrades and downgrades for ATYR from analysts
• ATYR’s stock price momentum as measured by its relative strength

About aTyr Pharma, Inc. (ATYR)

Before we jump into aTyr Pharma, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Want to learn more about aTyr Pharma, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about aTyr Pharma, Inc..

aTyr Pharma, Inc.’s Stock Price as of Market Close

As of June 03, 2026, 1:01 PM, CST, aTyr Pharma, Inc.’s stock price was $0.508.

aTyr Pharma, Inc. is down 2.37% from its previous closing price of $0.520.

During the last market session, aTyr Pharma, Inc.’s stock traded between $0.503 and $0.530. Currently, there are approximately 98.04 million shares outstanding for aTyr Pharma, Inc..

aTyr Pharma, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

aTyr Pharma, Inc. Stock Price History

aTyr Pharma, Inc.’s (ATYR) price is currently down 6.41% so far this month.

During the month of June, aTyr Pharma, Inc.’s stock price has reached a high of $0.590 and a low of $0.503.

Over the last year, aTyr Pharma, Inc. has hit prices as high as $7.290 and as low as $0.395. Year to date, aTyr Pharma, Inc.’s stock is down 35.17%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused aTyr Pharma, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 02, 2026, there was 1 analyst who downgraded aTyr Pharma, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate aTyr Pharma, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on aTyr Pharma, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

aTyr Pharma, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about aTyr Pharma, Inc. (ATYR) by visiting AAII Stock Evaluator.

Relative Price Strength of aTyr Pharma, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 02, 2026, aTyr Pharma, Inc. has a weighted four-quarter relative price strength of -30.20%, which translates to a Momentum Score of 5 and is considered to be Very Weak.

Want to learn more about how aTyr Pharma, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

aTyr Pharma, Inc. Stock Price: Bottom Line

As of June 3, 2026, aTyr Pharma, Inc.’s stock price is $0.508, which is down 2.37% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like aTyr Pharma, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.